ABSORB PHYSIOLOGY Clinical Investigation: Clinical Evaluation of the Short and Long-Term Effects of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold on Coronary Artery Blood Flow and Physiological Responsiveness
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Pharmacodynamics
- Acronyms ABSORB PHYSIOLOGY
- Sponsors Abbott Vascular
- 01 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Feb 2013 New trial record